Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: A randomized, comparative, observer-blinded study

British Journal of Dermatology

Volumn 170, Issue 6, 2014, Pages 1341-1349

  Kanwar, A J ^a   Vinay, K ^a   Sawatkar, G U ^a   Dogra, S ^a   Minz, R W ^a   Shear, N H ^b   Koga, H ^c   Ishii, N ^c   Hashimoto, T ^c  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF TORONTO   (Canada)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CORTICOSTEROID; DESMOGLEIN 1; DESMOGLEIN 3; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMATOUS PEMPHIGUS; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; IMMUNOLOGY; LYMPHOCYTOPENIA; METABOLISM; MIDDLE AGED; PEMPHIGUS; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIGENS, CD19; B-LYMPHOCYTES; DERMATOLOGIC AGENTS; DESMOGLEIN 1; DESMOGLEIN 3; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; PEMPHIGUS; PILOT PROJECTS; RECURRENCE; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903156216     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12972     Document Type: Article

References (32)

1. Schmidt E, Goebeler M, Zillikens D,. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-91.
2. Kanwar AJ, Tsuruta D, Vinay K, et al,. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol 2013; 27: e17-23.
3. Reguiai Z, Tabary T, Maizieres M, Bernard P,. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol 2012; 67: 623-9.
4. Craythorne EE, Mufti G, DuVivier AW,. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2011; 65: 1064-5.
5. Nigam R, Levitt J,. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease? J Drugs Dermatol 2012; 11: 622-5.
6. Kanwar AJ, Vinay K,. Rituximab in pemphigus. Indian J Dermatol Venereol Leprol 2012; 78: 671-6.
7. Leventhal JS, Sanchez MR,. Is it time to re-evaluate the treatment of pemphigus? J Drugs Dermatol 2012; 11: 1200-6.
8. Kanwar AJ, Sawatkar GU, Vinay K, Hashimoto T,. Childhood pemphigus vulgaris successfully treated with rituximab. Indian J Dermatol Venereol Leprol 2012; 78: 632-4.
9. Fuertes I, Guilabert A, Mascaro JM Jr, Iranzo P,. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology 2010; 221: 13-16.
10. Schmidt E, Herzog S, Brocker EB, et al,. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153: 449-51.
11. Joly P, Mouquet H, Roujeau JC, et al,. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
12. Goh MS, McCormack C, Dinh HV, et al,. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007; 156: 990-6.
13. Cianchini G, Corona R, Frezzolini A, et al,. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-8.
14. Cianchini G, Lupi F, Masini C, et al,. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012; 67: 617-22.
15. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al,. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
16. Rubbert-Roth A, Tak PP, Zerbini C, et al,. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49: 1683-93.
17. Horvath B, Huizinga J, Pas HH, et al,. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166: 405-12.
18. Cho HH, Jin SP, Chung JH,. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol 2013; doi: 10.1111/jdv.12080 (in press).
19. Ikeda S, Imamura S, Hashimoto I, et al,. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295 (Suppl. 1): S12-16.
20. Saraswat A, Bhushan K, India C,. A new grading system for oral pemphigus. Int J Dermatol 2003; 42: 413-14.
21. Murrell DF, Dick S, Ahmed AR, et al,. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.
22. Ishii K, Amagai M, Hall RP, et al,. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-17.
23. Popa C, Leandro MJ, Cambridge G, Edwards JC,. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626-30.
24. Leuci S, Levine D, Zhang J, Razzaque Ahmed A,. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 2009; 144: 379-409.
25. Bai S, Jorga K, Xin Y, et al,. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51: 119-35.
26. Ng CM, Bruno R, Combs D, Davies B,. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
27. Leshem YA, Hodak E, David M, et al,. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 2013; 68: 404-11.
28. Kasperkiewicz M, Schmidt E, Zillikens D,. Current therapy of the pemphigus group. Clin Dermatol 2012; 30: 84-94.
29. Sitaru C, Thiel J,. The need for markers and predictors of Rituximab treatment resistance. Exp Dermatol 2014; 23: 236-7.
30. Breedveld F, Agarwal S, Yin M, et al,. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119-28.
31. Feldman RJ, Christen WG, Ahmed AR,. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol 2012; 166: 511-17.
32. Abasq C, Mouquet H, Gilbert D, et al,. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145: 529-35.